中国大陆的喘流行病学:系统性审查和元分析
Jiarui Yu1,2, Liang Xu3, Azhu Han4,5
1First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, 233004, China.
BMC public health
|October 21, 2024
概括
中国的喘患病率为2.20%,增长趋势和区域差异. 预测显示,到2050年,这一数字将大幅上升,需要制定有针对性的公共卫生战略.
科学领域:
- 流行病学 流行病学
- 公共卫生 公共卫生
- 呼吸系统医学 呼吸系统医学
背景情况:
- 准确的喘患病率数据对于中国有效的公共卫生政策至关重要.
- 现有研究显示存在差异,阻碍了公共卫生规划.
- 这项研究提供了对中国喘的综合流行病学评估.
研究的目的:
- 对中国的喘患病率进行系统审查和元分析.
- 为了确定喘患病率的人口和地理差异.
- 分析趋势,并预测中国未来的喘患病率.
主要方法:
- 在多个数据库 (PubMed,Embase,CNKI等) 进行系统的文献审查. 在2023年8月之前.
- 包括192项研究在17,152个已识别的文章中,符合标准.
- 使用随机效应模型进行元分析,以确定整体和子组的流行率.
主要成果:
- 在中国,整体喘患病率为2.20% (95% CI:1.96-2.47%).
- 类似喘症状的发病率更高 (14.36%,目前为3.01%).
- 在男性,儿童,老年人,城市地区和中国东部观察到更高的患病率;从0.69% (1984) 增加到5.30% (2021).
结论:
- 中国的喘患病率正在增加,虽然比西方国家低.
- 喘负担存在显著的人口和地区差异.
- 高质量的流行病学研究对于明智的决策和未来的研究至关重要.
更多相关视频
05:56A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
Published on: May 12, 2023
3.3K
05:19Author Spotlight: An Effective Traditional Chinese Medicinal Treatment for Chronic Obstructive Pulmonary Disease with Abdominal Distension
Published on: September 1, 2023
1.3K
相关概念视频
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma: Pathogenesis and Management
361
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
361
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
240
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
240
